Wave Life Sciences Ltd. (WVE) DCF Valuation
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Wave Life Sciences Ltd. (WVE) Bundle
Looking to gauge the intrinsic value of Wave Life Sciences Ltd.? Our WVE DCF Calculator integrates real-world data with extensive customization features, allowing you to tailor your forecasts and enhance your investment choices.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16.0 | 20.1 | 41.0 | 3.6 | 113.3 | 151.4 | 202.3 | 270.4 | 361.3 | 482.8 |
| Revenue Growth, % | 0 | 25.61 | 104.03 | -91.09 | 3005.1 | 33.63 | 33.63 | 33.63 | 33.63 | 33.63 |
| EBITDA | -200.7 | -143.4 | -117.2 | -152.6 | -58.8 | -136.8 | -182.9 | -244.4 | -326.5 | -436.4 |
| EBITDA, % | -1255.89 | -714.22 | -286.06 | -4182.13 | -51.89 | -90.38 | -90.38 | -90.38 | -90.38 | -90.38 |
| Depreciation | 9.2 | 10.0 | 9.8 | 10.1 | 9.2 | 72.5 | 96.9 | 129.5 | 173.0 | 231.2 |
| Depreciation, % | 57.57 | 49.72 | 24.01 | 277.17 | 8.12 | 47.88 | 47.88 | 47.88 | 47.88 | 47.88 |
| EBIT | -209.9 | -153.4 | -127.0 | -162.7 | -68.0 | -139.3 | -186.1 | -248.8 | -332.4 | -444.2 |
| EBIT, % | -1313.46 | -763.94 | -310.07 | -4459.3 | -60.01 | -92 | -92 | -92 | -92 | -92 |
| Total Cash | 147.2 | 184.5 | 150.6 | 88.5 | 200.4 | 151.4 | 202.3 | 270.4 | 361.3 | 482.8 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 20.0 | 30.0 | .0 | .0 | 21.1 | 66.2 | 88.5 | 118.2 | 158.0 | 211.1 |
| Account Receivables, % | 125.13 | 149.42 | 0 | 0 | 18.61 | 43.72 | 43.72 | 43.72 | 43.72 | 43.72 |
| Inventories | 9.6 | 10.4 | .0 | .0 | .0 | 34.0 | 45.4 | 60.7 | 81.1 | 108.3 |
| Inventories, % | 60.23 | 51.97 | 0 | 0 | 0 | 22.44 | 22.44 | 22.44 | 22.44 | 22.44 |
| Accounts Payable | 9.1 | 13.8 | 7.3 | 16.9 | 12.8 | 77.1 | 103.0 | 137.7 | 184.0 | 245.8 |
| Accounts Payable, % | 56.77 | 68.71 | 17.77 | 463.55 | 11.33 | 50.92 | 50.92 | 50.92 | 50.92 | 50.92 |
| Capital Expenditure | -3.9 | -1.3 | -.6 | -1.4 | -1.1 | -21.4 | -28.7 | -38.3 | -51.2 | -68.4 |
| Capital Expenditure, % | -24.51 | -6.66 | -1.37 | -37.3 | -0.98407 | -14.17 | -14.17 | -14.17 | -14.17 | -14.17 |
| Tax Rate, % | 1.16 | 1.16 | 1.16 | 1.16 | 1.16 | 1.16 | 1.16 | 1.16 | 1.16 | 1.16 |
| EBITAT | -194.6 | -152.5 | -126.8 | -163.4 | -67.2 | -136.7 | -182.7 | -244.2 | -326.3 | -436.0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -209.9 | -150.0 | -83.6 | -145.0 | -84.3 | -100.5 | -122.3 | -163.4 | -218.3 | -291.8 |
| WACC, % | 5.36 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -746.9 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -298 | |||||||||
| Terminal Value | -8,829 | |||||||||
| Present Terminal Value | -6,797 | |||||||||
| Enterprise Value | -7,544 | |||||||||
| Net Debt | -168 | |||||||||
| Equity Value | -7,376 | |||||||||
| Diluted Shares Outstanding, MM | 106 | |||||||||
| Equity Value Per Share | -69.52 |
What You Will Get
- Comprehensive WVE Financials: Access to historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures to fit your analysis.
- Dynamic Calculations: Intrinsic value and NPV are computed in real-time.
- Scenario Analysis: Explore various scenarios to assess Wave Life Sciences' future performance.
- User-Friendly Design: Designed for industry experts while remaining approachable for newcomers.
Key Features
- Customizable Research Metrics: Adjust essential factors such as drug development timelines, market potential, and operational costs.
- Instant Valuation Insights: Provides real-time calculations of intrinsic value, NPV, and other key financial indicators.
- Industry-Leading Precision: Utilizes Wave Life Sciences Ltd.'s (WVE) actual financial data for accurate valuation results.
- Effortless Scenario Testing: Easily evaluate various hypotheses and analyze their potential impacts.
- Efficiency Booster: Streamline the valuation process without the hassle of constructing intricate models from the ground up.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Wave Life Sciences data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Wave Life Sciences' intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose This Calculator for Wave Life Sciences Ltd. (WVE)?
- Designed for Experts: A sophisticated tool tailored for researchers, biopharmaceutical analysts, and investment professionals.
- Accurate Data: Wave Life Sciences’ historical and projected financials are preloaded for precision.
- Flexible Scenario Analysis: Effortlessly model various forecasts and assumptions.
- Insightful Outputs: Automatically computes intrinsic value, NPV, and essential performance metrics.
- User-Friendly: Comprehensive step-by-step guidance ensures a smooth experience.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling Wave Life Sciences Ltd. (WVE) stock.
- Financial Analysts: Enhance valuation processes with comprehensive financial models tailored for Wave Life Sciences Ltd. (WVE).
- Consultants: Provide clients with expert valuation insights on Wave Life Sciences Ltd. (WVE) swiftly and accurately.
- Business Owners: Gain insights into how biopharmaceutical companies like Wave Life Sciences Ltd. (WVE) are valued to inform your own business strategy.
- Finance Students: Explore valuation techniques using real-world data and case studies focused on Wave Life Sciences Ltd. (WVE).
What the Template Contains
- Pre-Filled Data: Includes Wave Life Sciences Ltd.'s historical financials and projections.
- Discounted Cash Flow Model: Editable DCF valuation model with automated calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on user-defined inputs.
- Key Financial Ratios: Evaluate Wave Life Sciences Ltd.'s profitability, efficiency, and leverage.
- Customizable Inputs: Easily modify revenue growth, profit margins, and tax rates.
- Clear Dashboard: Visual representations and tables summarizing essential valuation outcomes.